- Home
- ADSE vs NMRA Comparison
ADSE vs NMRA Comparison
Compare ADSE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADSE | NMRA |
|---|---|---|
| Founded | 1980 | 2019 |
| Country | Ireland | United States |
| Employees | 302 | N/A |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 691.4M | 554.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | ADSE | NMRA |
|---|---|---|
| Price | $10.63 | $2.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $6.57 |
| AVG Volume (30 Days) | 4.6K | ★ 1.1M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $219.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.89 | $0.63 |
| 52 Week High | $14.05 | $3.65 |
Technical Indicators
Market Signals| Indicator | ADSE | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 35.52 |
| Support Level | $10.14 | $2.10 |
| Resistance Level | $12.53 | $2.20 |
| Average True Range (ATR) | 0.55 | 0.17 |
| MACD | 0.03 | -0.07 |
| Stochastic Oscillator | 45.92 | 27.78 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.